An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions

References

• Colamonico J, Formella A, Bradley W. Pseudobulbar affect: burden of illness in the USA. Adv Ther 2012;29:775-98
   PubMed Web of Science ®Google Scholar
• Wortzel HS, Oster TJ, Anderson CA, Arciniegas DB. Pathological laughing and crying: epidemiology, pathophysiology and treatment. CNS Drugs 2008;22:531-45
   PubMed Web of Science ®Google Scholar
• Parvizi J, Arciniegas DB, Bernardini GL, et al. Diagnosis and management of pathological laughter and crying. Mayo Clin Proc 2006;81:1482-6
   PubMed Web of Science ®Google Scholar
• Work S, Colamonico JA, Bradley WG, Kaye RE. Pseudobulbar affect: an under-recognized and undertreated neurological disorder. Adv Ther 2011;28:586-601
   PubMed Web of Science ®Google Scholar
• Brooks BR, Crumpacker D, Fellus J, et al. PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions. PLoS One 2013;8:1-8
   Web of Science ®Google Scholar
• Lopez OL, Gonzalez MP, Becker JT, et al. Symptoms of depression and psychosis in Alzheimer’s disease and frontotemporal dementia: exploration of underlying mechanisms. Neuropsychiatry Neuropsychol Behav Neurol 1996;9:154-61
   Google Scholar
• Feinstein A, Feinstein K, Gray T, O’Connor P. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997;54:1116-21
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Fernandez HH, Garvan CW, et al. Inappropriate crying and laughing in Parkinson disease and movement disorders. World J Biol Psychiatry 2009;10:234-40
   PubMed Web of Science ®Google Scholar
• House A, Dennis M, Molyneux A, et al. Emotionalism after stroke. BMJ 1989;298:991-4
   PubMed Web of Science ®Google Scholar
• Tateno A, Jorge RE, Robinson RG. Pathological laughing and crying following traumatic brain injury. J Neuropsychiatry Clin Neurosci 2004;16:426-34
   PubMed Web of Science ®Google Scholar
• Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989;80:114-17
   PubMed Web of Science ®Google Scholar
• Parvizi J, Anderson SW, Martin CO, et al. Pathological laughter and crying: a link to the cerebellum. Brain 2001;124:1708-19
   PubMed Web of Science ®Google Scholar
• Parvizi J, Joseph J, Press DZ, Schmahmann JD. Pathological laughing and crying in patients with multiple system atrophy-cerebellar type. Mov Disord 2007;22:798-803
   PubMed Web of Science ®Google Scholar
• Parvizi J, Coburn KL, Shillcutt SD, et al. Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci 2009;21:75-87
   PubMed Web of Science ®Google Scholar
• Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) capsules. Full prescribing information. Available at: https://www.nuedexta.com/sites/default/files/pdf/Prescribing_Information.pdf [Last accessed 14 March 2014]
   Google Scholar
• European Medicines Agency. Nuedexta. Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002560/WC500145050.pdf [Last accessed 14 March 2014]
   Google Scholar
• Choi DW, Peters S, Viseskul V. Dextrorphan and levorphanol selectively block N-Methyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons. J Pharmacol Exp Ther 1987;242:713-20
   PubMed Web of Science ®Google Scholar
• Musacchio JM, Klein M, Canoll PD. Dextromethorphan and sigma ligands: common sites but diverse effects. Life Sci 1989;45:1721-32
   PubMed Web of Science ®Google Scholar
• Werling LL, Keller A, Frank JG, Nuwayhid SJ. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol 2007;207:248-57
   PubMed Web of Science ®Google Scholar
• Zhang Y, Britto MR, Valderhaug KL, et al. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992;51:647-55
   PubMed Web of Science ®Google Scholar
• Pope LE, Khalil MH, Berg JE, et al. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol 2004;44:1132-42
   PubMed Web of Science ®Google Scholar
• Brooks BR, Thisted RA, Appel SH, et al.; AVP-923 ALS Study Group. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364-70
   PubMed Web of Science ®Google Scholar
• Panitch HS, Thisted RA, Smith RA, et al.; Pseudobulbar Affect in Multiple Sclerosis Study Group. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006;59:780-7
   PubMed Web of Science ®Google Scholar
• Pioro EP, Brooks BR, Cummings J, et al.; Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010;68:693-702
   PubMed Web of Science ®Google Scholar
• Gil J, Funalot B, Verschueren A, et al. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol 2008;15:1245-51
   PubMed Web of Science ®Google Scholar
• Spataro R, Lo Re M, Piccoli T, et al. Causes and place of death in Italian patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2010;122:217-23
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-91
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Weverling GJ, Bossuyt PM, et al. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52:559-64
   PubMed Web of Science ®Google Scholar
• Rooney J, Byrne S, Heverin M, et al. Survival analysis of Irish amyotrophic lateral sclerosis patients diagnosed from 1995–2010. PLoS One 2013;8:e74733
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, et al.; SLAP Registry. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2008;79:33-7
   PubMed Web of Science ®Google Scholar
• Murphy M, Quinn S, Young J, et al. Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study. Neurology 2008;71:1889-95
   PubMed Web of Science ®Google Scholar
• del Aquila MA, Longstreth WT Jr, McGuire V, et al. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60:813-19
   PubMed Web of Science ®Google Scholar
• Chiò A, Mora G, Leone M, et al.; Piemonte and Valle d’Aosta Register for ALS (PARALS). Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:99-103
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, et al.; EURALS. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 2008;79:6-11
   PubMed Web of Science ®Google Scholar
• Millul A, Beghi E, Logroscino G, et al. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology 2005;25:114-19
   PubMed Web of Science ®Google Scholar
• Quinidine Sulfate Tablets USP Revised: June 2005 Rx only. Available at: http://pi.watson.com/data_stream.asp?product_group=1306&p=pi [Last accessed 14 March 2014]
   Google Scholar
• Holford NH, Coates PE, Guentert TW, et al. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration–effect relationships. Br J Clin Pharmacol 1981;11:187-95
   PubMed Web of Science ®Google Scholar
• Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-16
   PubMed Web of Science ®Google Scholar
• Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis. Circulation 1991;84:1977-83
   PubMed Web of Science ®Google Scholar
• Grace AA, Camm AJ. Quinidine. N Engl J Med 1998;338:35-45
   PubMed Web of Science ®Google Scholar